Refractory Status Epilepticus: Choosing the Continuous Infusion Agent
A 29-year-old teacher's first seizure never stopped, even after benzodiazepines and a second-line load. The next drug has to achieve burst suppression in a patient whose blood pressure is already sliding.
J.K., a 29-year-old woman, teaches second grade and had spent the summer training for her first half marathon — nothing in her history suggested this was coming. She collapsed convulsing in the school parking lot after drop-off, and by the time EMS arrived she had already been seizing for several minutes. Two doses of lorazepam en route didn't stop it; a levetiracetam load in the emergency department, dosed per the ESETT protocol that has become the standard second-line step once benzodiazepines alone fail, didn't stop it either. Twenty minutes past that load, still convulsing, she met the definition the team had been trying to avoid needing: refractory status epilepticus, now requiring a continuous infusion anesthetic to achieve burst suppression, the phase of treatment ESETT's own protocol was never designed to reach.
Her blood pressure — 88/54, drawn after two rounds of benzodiazepines and an ongoing seizure burden — is already trending down before anyone starts an anesthetic infusion, and that number bears directly on which agent she can tolerate. Claassen and colleagues' 2002 systematic review of continuous infusion therapy for refractory status epilepticus found pentobarbital more reliably achieved seizure control than midazolam or propofol, but at a real hemodynamic cost: hypotension requiring vasopressor support followed roughly three-quarters of pentobarbital courses, against a substantially lower rate for the other two agents. She is 29, otherwise healthy, with normal renal and hepatic function — exactly the patient in whom propofol's short context-sensitive half-life would normally make it the clean first choice, letting the team lighten sedation for a neurologic exam without hours of lag. The complication is that her own blood pressure, not her liver or kidneys, is what's already trending in the wrong direction, and propofol is not hemodynamically free either.
Choosing what to run next
Her pressure is already 88 over 54 before we've given a milligram of the drug we're about to start, and propofol drops systemic vascular resistance on top of whatever's driving that. I'd start midazolam — it's gentler on initiation, and we're early enough in this course that accumulation over the next few hours isn't the concern it becomes on day three.
You're right that propofol isn't hemodynamically free — but midazolam's advantage there is really only true for the first few hours. If this doesn't break quickly, and refractory status often doesn't, midazolam's lipophilic redistribution starts working against us: it accumulates, the wean stretches out, and we lose the ability to tell seizure recurrence from residual sedation. I want the drug I can turn off and actually see her.
The pressure of 88/54 predates the infusion decision entirely — that's two rounds of lorazepam plus the metabolic cost of a prolonged convulsion, not a preview of what propofol will do to her. Start propofol with a controlled bolus rather than a rapid load, titrate to burst suppression, and treat any further pressure drop as something to support with a vasopressor rather than a reason to abandon the agent that preserves our ability to examine her. Keep pentobarbital named and ready — Claassen's data say it's the more reliable second step if propofol doesn't achieve suppression, not the first.
Propofol achieved burst suppression within ninety minutes of a controlled load, and her pressure held with a low-dose norepinephrine infusion started proactively rather than reactively. EEG was weaned to intermittent lightening after twelve hours without seizure recurrence.
Not fully agreed: the anesthesiologist maintains that starting midazolam and converting to propofol only if the course extended would have been the more conservative hemodynamic path, a position the good outcome here didn't disprove so much as leave untested. CK and triglycerides are being trended every 48 hours given the propofol infusion's expected duration.